Adipose dreived allogeneic stem cell therapy - Cambium Bio
Alternative Names: PRG; Progenza™Latest Information Update: 28 Jul 2025
At a glance
- Originator Regeneus ltd
- Developer Cambium Bio
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Cytokine stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Osteoarthritis
- No development reported Neuropathic pain
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Neuropathic-pain in Australia (Intra-articular)
- 20 Jul 2023 Preclinical development is ongoing for Neuropathic pain in Australia (Regeneus pipeline, July 2023)
- 02 Jan 2023 Adipose dreived allogeneic stem cell therapy is still in phase-II clinical trials for Osteoarthritis in Australia (Intra-articular) (Regeneus pipeline, January 2023)